PhRMA Statement on Presidential Commission on the Opioid Abuse Epidemic
WASHINGTON, D.C. (March 29, 2017) — The Pharmaceutical Research and Manufacturers of America (PhRMA) today released the following statement on the presidential commission to study the opioid abuse epidemic in the U.S.:
“We are pleased to see the Administration announce a focus on combatting the opioid crisis and we look forward to working with them on this important issue. This public health crisis resulting from abuse of heroin and prescription opioids is complex and far-reaching, impacting communities and families around the country. PhRMA is committed to working with the Administration and other stakeholders on ways we can collectively work together help prevent and combat prescription drug abuse.”
Last year, PhRMA released a comprehensive set of policy recommendations to help curb prescription drug abuse and promote appropriate use of prescription medicines. The recommendations included improving prescriber education and training, improving the effectiveness of prescription drug monitoring programs (PDMPs), strengthening efforts to combat drug diversion and improving coverage for alternative treatment options for pain. Additionally, PhRMA members have worked to develop abuse-deterrent formulations (ADFs) for brand medications to help reduce the risk of abuse.
You can read more about PhRMA’s proposals to curb prescription drug abuse and misuse here.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: